InVivo Therapeutics (NVIVQ) 10-Q 10 May 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 05, 2021
Document and Entity Information
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Entity Registrant Name	InVivo Therapeutics Holdings Corp.
Entity Current Reporting Status	Yes
Title of 12(b) Security	Common Stock
Trading Symbol	NVIV
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		34,264,756
Entity Central Index Key	0001292519
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 24,767	$ 19,493
Prepaid expenses and other current assets	751	163
Total current assets	25,518	19,656
Property, equipment and leasehold improvements, net	76	85
Restricted cash - non current	110	110
Operating lease right-of-use assets	853	928
Prepaid clinical trial expenses	1,122	1,122
Other assets	4	9
Total assets	27,683	21,910
Current liabilities:
Accounts payable	640	481
Operating lease liabilities	336	327
Accrued expenses	499	1,164
Total current liabilities	1,475	1,972
Other liabilities	79	59
Operating lease liabilities - non current	605	693
Total liabilities	2,159	2,724
Commitments and contingencies (Note 5)
Stockholders’ equity:
Common stock, $0.00001 par value, authorized 50,000,000 shares; 34,264,756 shares issued and outstanding, including 6,302 shares of unvested restricted stock, at March 31, 2021; authorized 50,000,000 shares; 23,631,886 shares issued and outstanding, including 6,302 shares of unvested restricted stock, at December 31, 2020	3	3
Additional paid-in capital	255,978	247,417
Accumulated deficit	(230,457)	(228,234)
Total stockholders’ equity	25,524	19,186
Total liabilities and stockholders’ equity	$ 27,683	$ 21,910

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020	Aug. 04, 2020	Aug. 03, 2020	Feb. 11, 2020	Jan. 21, 2020	May 31, 2018
Common stock, par value (in dollars per share)	$ 0.00001	$ 0.00001			$ 0.00001
Common stock, authorized	50,000,000	50,000,000	50,000,000	16,666,667	16,666,667	500,000,000	25,000,000
Common stock, issued	34,264,756	23,631,886
Common stock, outstanding	34,264,756	23,631,886
Restricted Stock [Member]
Common stock, outstanding	6,302	6,302

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating expenses:
Research and development	$ 1,012	$ 1,051
General and administrative	1,212	1,377
Total operating expenses	2,224	2,428
Operating loss	(2,224)	(2,428)
Other income:
Interest income	1	14
Other income	1	14
Net loss	$ (2,223)	$ (2,414)
Net loss per share, basic and diluted (in dollars per share)	$ (0.08)	$ (2.47)
Weighted average number of common shares outstanding, basic and diluted (In Shares)	29,473,621	976,121

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning balance at Dec. 31, 2019	$ 2	$ 224,741	$ (219,160)	$ 5,583
Beginning Balance, (in shares) at Dec. 31, 2019	550,736
Share-based compensation expense		70		70
Fractional shares issued due to reverse stock split	7,692
Issuance of common stock and warrants in public offering		6,035		6,035
Issuance of common stock and warrants in public offering (in shares)	955,613
Issuance of common stock upon exercise of warrants		286		286
Issuance of common stock upon exercise of warrants (in shares)	1,057,512
Net loss			(2,414)	(2,414)
Ending balance at Mar. 31, 2020	$ 2	231,132	(221,574)	9,560
Ending Balance, (in shares) at Mar. 31, 2020	2,571,553
Beginning balance at Dec. 31, 2020	$ 3	247,417	(228,234)	$ 19,186
Beginning Balance, (in shares) at Dec. 31, 2020	23,631,886			23,631,886
Share-based compensation expense		52		$ 52
Issuance of common stock upon exercise of warrants		8,509		8,509
Issuance of common stock upon exercise of warrants (in shares)	10,632,870
Net loss			(2,223)	(2,223)
Ending balance at Mar. 31, 2021	$ 3	$ 255,978	$ (230,457)	$ 25,524
Ending Balance, (in shares) at Mar. 31, 2021	34,264,756			34,264,756

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)	Feb. 11, 2020	Mar. 31, 2020
Consolidated Statements of Changes in Stockholders' Equity (Deficit)
Reverse stock split ratio	0.0333	0.03333

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (2,223)	$ (2,414)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	14	11
Amortization of operating lease right-of-use assets	75	69
Share-based compensation expense	52	70
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(588)	(590)
Accounts payable	159	46
Operating lease liability	(79)	(71)
Accrued expenses and other liabilities	(645)	(843)
Net cash used in operating activities	(3,235)	(3,722)
Cash flows from financing activities:
Proceeds from exercise of warrants	8,509	286
Proceeds from issuance of common stock and warrants, net of commissions and issuance costs		6,035
Net cash provided by financing activities	8,509	6,321
Increase in cash and cash equivalents and restricted cash	5,274	2,599
Cash, cash equivalents and restricted cash at beginning of period	19,603	6,716
Cash, cash equivalents and restricted cash at end of period	$ 24,877	9,315
Supplemental disclosure of cash flow information and non-cash investing and financing activities:
Fair value of warrants issued in connection with the financing activities		$ 3,683

NATURE OF OPERATIONS AND GOING

NATURE OF OPERATIONS AND GOING CONCERN, BASIS OF PRESENTATION AND RECENT ACCOUNTING PRONOUNCEMENTS	3 Months Ended
	Mar. 31, 2021
NATURE OF OPERATIONS AND GOING CONCERN, BASIS OF PRESENTATION AND RECENT ACCOUNTING PRONOUNCEMENTS
NATURE OF OPERATIONS AND GOING CONCERN, BASIS OF PRESENTATION AND RECENT ACCOUNTING PRONOUNCEMENTS	1. Business InVivo Therapeutics Holdings Corp., including its subsidiary, (the “Company”) is a biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries (“SCIs”). The Company’s proprietary technologies incorporate intellectual property that is licensed under an exclusive, worldwide license from Boston Children’s Hospital (“BCH”) and the Massachusetts Institute of Technology (“MIT”), as well as intellectual property that has been developed internally in collaboration with its advisors and partners. Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets, and raising capital. The Company has historically financed its operations primarily through the sale of equity-related securities. As of March 31, 2021, the Company had unrestricted consolidated cash and cash equivalents of $24.8 million. Given the Company’s current plans, the Company estimates cash resources will be sufficient to fund its operations through the second quarter of 2023. The Company has not achieved profitability and may not be able to realize sufficient revenue to achieve or sustain profitability in the future. The Company does not expect to be profitable in the next several years, but rather expects to incur additional operating losses. The Company has limited liquidity and capital resources and must obtain significant additional capital resources in order to sustain its product development efforts, for acquisition of technologies and intellectual property rights, for preclinical and clinical testing of its anticipated products, pursuit of regulatory approvals, acquisition of capital equipment, laboratory and office facilities, establishment of production capabilities, for selling, general and administrative expenses, and other working capital requirements. The Company may raise capital through a combination of equity offerings, debt financings, other third-party funding, marketing and distribution arrangements, and other collaborations, strategic alliances, and licensing arrangements. The Company believes that it can be successful in obtaining additional capital; however, no assurance can be provided that it will be able to do so. There is no assurance, moreover, that any funds raised will be sufficient to enable the Company to attain profitable operations or continue as a going concern. As a result of the COVID-19 pandemic, a significant number of the Company’s clinical sites temporarily suspended enrollment into the INSPIRE 2.0 Study at their institution in 2020. As such, the COVID-19 pandemic did affect and may continue to affect the potential for enrollment in the Company’s INSPIRE 2.0 Study in the event that clinical sites may again suspend studies in the future in order to manage the pandemic. Aside from the impact on enrollment in the Company’s INSPIRE 2.0 Study, the Company did not experience any significant impact from the COVID-19 pandemic on its financial condition, liquidity, other operations, suppliers, industry, and workforce during the three months ended March 31, 2021. As of May 7, 2021 the Company has 18 clinical sites open for enrollment in the INSPIRE 2.0 Study, which is the total number of sites it had activated for the INSPIRE 2.0 Study. The full impact of the COVID-19 pandemic continues to evolve as of the date of filing this Quarterly Report on Form 10-Q, and the Company cannot be certain what future impact the COVID-19 pandemic may have on its clinical sites and their respective abilities to enroll patients. As the pandemic continues to evolve, there may be additional government actions or disruptions that could cause the Company’s clinical sites to suspend or alter operations in a manner that would impact enrollment of the INSPIRE 2.0 Study. The Company is actively monitoring the impact of the global situation on its financial condition, liquidity, operations, suppliers, industry, and workforce, as there remains significant uncertainty related to the COVID-19 pandemic globally. Given the daily evolution of the COVID-19 pandemic and the global responses to curb its spread, the Company is not able to estimate the ultimate effects of the COVID-19 pandemic on its future results of operations, financial condition, or liquidity in the future. However, as the COVID-19 pandemic continues, it may continue to have an adverse effect on enrollment in the Company’s INSPIRE 2.0 Study, and may also have an adverse effect on the Company’s results of future operations, financial position, and liquidity, and even after the COVID-19 pandemic has subsided, the Company may continue to experience adverse impacts to its business as a result of any economic recession or depression that has occurred or may occur in the future. Going Concern The Company’s consolidated financial statements as of March 31, 2021 were prepared under the assumption that the Company will continue as a going concern. As of March 31, 2021, the Company had unrestricted cash and cash equivalents of $24.8 million. Given the Company’s current development plans, the Company estimates cash resources will be sufficient to fund its operations, through the second quarter of 2023. The Company’s ability to continue as a going concern depends on its ability to obtain additional equity or debt financing, attain further operating efficiencies, manage expenditures, and, ultimately, to generate revenue. If the Company is unable to continue as a going concern, it may have to liquidate its assets and may receive less than the value at which those assets are carried on its audited financial statements, and it is likely that investors will lose all or part of their investment. Reverse Stock Split On February 11, 2020, the Company effected a reverse stock split of its common stock, par value $0.00001 per share, at a ratio of 1-for-30 (the “2020 Reverse Stock Split”). As a result of the 2020 Reverse Stock Split, (i) every 30 shares of the issued and outstanding common stock were automatically converted into one newly issued and outstanding share of common stock, without any change in the par value per share; (ii) the number of shares of common stock into which each outstanding warrant or option to purchase common stock is exercisable was proportionally decreased, and (iii) the number of authorized shares of common stock outstanding was proportionally decreased. Shares of common stock underlying outstanding stock options and other equity instruments convertible into common stock were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. All of the Company’s historical share and per share information related to issued and outstanding common stock and outstanding options and warrants exercisable for common stock in these consolidated financial statements were adjusted, on a retroactive basis to reflect the 2020 Reverse Stock Split. Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) consistent with those applied in, and should be read in conjunction with, the Company’s audited consolidated financial statements and related footnotes for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K as filed with the United States Securities and Exchange Commission (“SEC”) on March 1, 2021. The unaudited consolidated financial statements reflect all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the Company’s financial position as of March 31, 2021 and its results of operations and cash flows for the interim periods presented, and are not necessarily indicative of results for subsequent interim periods or for the full year. The interim consolidated financial statements do not include all of the information and footnotes required by U.S. GAAP for complete financial statements, as allowed by the relevant SEC rules and regulations; however, the Company believes that its disclosures are adequate to ensure that the information presented is not misleading.

CASH AND CASH EQUIVALENTS

CASH AND CASH EQUIVALENTS	3 Months Ended
	Mar. 31, 2021
CASH AND CASH EQUIVALENTS
CASH AND CASH EQUIVALENTS	2. CASH AND CASH EQUIVALENTS The Company considers only those investments that are highly liquid, readily convertible to cash, and that mature within 3 months from date of purchase to be cash equivalents. From time to time, the Company may have cash balances in financial institutions in excess of insurance limits. The Company has not experienced any losses related to these balances. Management believes it is not exposed to significant credit risk. Cash and cash equivalents consisted of the following: March 31, December 31, (In thousands) 2021 2020 Cash $ 52 $ (13) Money market funds 24,715 19,506 Total cash and cash equivalents $ 24,767 $ 19,493

RESTRICTED CASH

RESTRICTED CASH	3 Months Ended
	Mar. 31, 2021
RESTRICTED CASH
RESTRICTED CASH	3. RESTRICTED CASH Restricted cash as of March 31, 2021 and December 31, 2020 was $110 thousand. Restricted cash as of each of March 31, 2021 and December 31, 2020 included a $50 thousand security deposit related to the Company’s credit card account and a $60 thousand standby letter of credit in favor of a landlord (see Note 5).

FAIR VALUES OF ASSETS AND LIABI

FAIR VALUES OF ASSETS AND LIABILITIES	3 Months Ended
	Mar. 31, 2021
FAIR VALUES OF ASSETS AND LIABILITIES
FAIR VALUES OF ASSETS AND LIABILITIES	4. FAIR VALUES OF ASSETS AND LIABILITIES The Company groups its assets and liabilities generally measured at fair value into three levels based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. Level 1 — Valuation is based on quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities generally include debt and equity securities that are traded in an active exchange market. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities. Level 2 — Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 — Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. Assets and liabilities measured at fair value on a recurring basis are summarized below: As of March 31, 2021 (In thousands) Level 1 Level 2 Level 3 Fair Value Cash equivalents $ 24,715 $ — $ — $ 24,715 As of December 31, 2020 (In thousands) Level 1 Level 2 Level 3 Fair Value Cash equivalents $ 19,506 $ — $ — $ 19,506 During the three months ended March 31, 2021 and 2020, there were no transfers between levels. The fair value of the Company’s cash equivalents, consisting of a money market fund, is based on quoted market prices in active markets with no valuation adjustment. The Company believes the carrying amounts of its prepaid expenses and other current assets, restricted cash, accounts payable and accrued expenses approximate their fair value due to the short-term nature of these amounts.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2021
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	5. COMMITMENTS AND CONTINGENCIES Operating Leases On May 3, 2018, the Company entered into a sublease for 5,104 square feet of space for its corporate offices and laboratory space in Cambridge, Massachusetts (the “Cambridge Lease”). The Cambridge Lease commenced on May 3, 2018 and expires on October 31, 2023 with no renewal options. The Cambridge Lease contains rent holiday and rent escalation clauses. In connection with the Cambridge Lease, a standby letter of credit was established for $40 thousand. On November 1, 2018, the standby letter of credit was increased to $60 thousand. Under the Cambridge Lease, the Company will be required to pay its proportionate share of certain operating costs and property taxes applicable to the leased premises in excess of new base year amounts. These costs are considered to be variable lease payments and are not included in the determination of the lease’s right-of-use asset or lease liability. The Company identified and assessed the following significant assumptions in recognizing its right-of-use assets and corresponding lease liabilities: · As the Cambridge Lease does not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company has estimated its incremental borrowing rate based on electing the remaining lease term as of the adoption date. · Since the Company elected to account for each lease component and its associated non-lease components as a single combined component, all contract consideration was allocated to the combined lease component. · The expected lease terms include noncancelable lease periods . The elements of lease expense are as follows: Three Months Ended March 31, Lease cost (In thousands) 2021 2020 Operating lease cost $ 91 $ 91 Short-term lease cost 2 8 Variable lease cost 27 25 Total lease cost $ 120 $ 124 Other information (In thousands) Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from short term leases $ 2 $ 8 Operating cash flows from operating leases 95 93 Total cash paid for leases $ 97 $ 101 Weighted-average remaining lease term - operating leases 2.6 Years 3.6 Years Weighted-average discount rate - operating leases Maturities of lease liabilities due under the Cambridge Lease as of March 31, 2021 is as follows: Leases (In thousands) As of March 31, 2021 2021(excluding the 3 months ended March 31, 2021) $ 290 2022 398 2023 339 Total lease payments 1,027 Less: imputed interest (86) Present value of lease liabilities $ 941 Right-of-use lease assets and lease liabilities are reported in the Company’s consolidated balance sheets as follows: Leases (In thousands) Classification March 31, 2021 December 31, 2020 Assets Lease asset, net Operating $ 853 $ 928 Total lease assets $ 853 $ 928 Liabilities Current Operating $ 336 $ 327 Non-current Operating 605 693 Total lease liabilities $ 941 $ 1,020 Clinical Trial Commitments The Company has engaged and executed contracts with clinical research organizations (“CROs”) to assist with the administration of its ongoing INSPIRE 1.0 and INSPIRE 2.0 clinical trials. As of March 31, approximately $4 million remains to be paid on these contracts. The timelines and related costs necessary to complete these trials may vary depending on a number of factors including the rate of patient enrollment into our INSPIRE 2.0 trial. In the event the Company were to terminate the INSPIRE 2.0 trial, certain financial penalties would become payable to the CROs for costs to wind down the terminated trial.

FIXED ASSETS

FIXED ASSETS	3 Months Ended
	Mar. 31, 2021
FIXED ASSETS
FIXED ASSETS	6. FIXED ASSETS Property, equipment, and leasehold improvements, net consisted of the following: March 31, December 31, (In thousands) 2021 2020 Computer software and hardware $ 40 $ 40 Research and lab equipment 520 520 Leasehold improvements 66 66 Property and equipment 626 626 Less accumulated depreciation (550) (541) Property and equipment, net $ 76 $ 85 Depreciation expense for the three months ended March 31, 2021 and 2020, was $9 thousand and $7 thousand, respectively. Maintenance and repairs are charged to expense as incurred and any additions or improvements are capitalized.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2021
INTANGIBLE ASSETS
INTANGIBLE ASSETS	7. INTANGIBLE ASSETS Intangible assets, included in “other assets,” consisted of patent licensing fees paid to license intellectual property. In July 2007, the Company entered into a worldwide exclusive license (the “BCH License”) for patents co-owned by BCH and MIT initially covering the use of biopolymers to treat spinal cord injuries, and to promote the survival and proliferation of human stem cells in the spinal cord. During 2011, the BCH License was amended, and the Company obtained additional rights for use in the field of peripheral nerve injuries. The BCH License, as amended, has a 15-year term, or as long as the life of the last expiring patent right thereunder, whichever is longer, unless terminated earlier by the licensor, under certain conditions as defined in the related license agreement. In connection with the BCH License, the Company paid an initial $75 thousand licensing fee and is required to pay certain annual maintenance fees, milestone payments and royalties. License fees are capitalized and the gross total as of March 31, 2021 and December 31, 2020 was $200 thousand. The Company accounts for milestone payments, maintenance fees and royalties when they become due and payable. During the three months ended March 31, 2021 and 2020, the Company did not pay any milestone payments. The Company is amortizing the license fee as a research and development expense over the 15-year term of the license. Intangible assets, net consisted of the following: March 31, December 31, (In thousands) 2021 2020 Patent licensing fee $ 200 $ 200 Accumulated amortization (196) (191) Other assets $ 4 $ 9 Amortization expense during the three months ended March 31, 2021 and 2020 was $5 thousand and $4 thousand, respectively.

ACCRUED EXPENSES

ACCRUED EXPENSES	3 Months Ended
	Mar. 31, 2021
ACCRUED EXPENSES.
ACCRUED EXPENSES	8. ACCRUED EXPENSES Accrued expenses consisted of the following: March 31, December 31, (In thousands) 2021 2020 Compensation $ 237 $ 996 Clinical 138 5 Legal 21 17 Other accrued expenses 103 146 Total accrued expenses $ 499 $ 1,164

EMPLOYEE BENEFIT PLAN

EMPLOYEE BENEFIT PLAN	3 Months Ended
	Mar. 31, 2021
EMPLOYEE BENEFIT PLAN
EMPLOYEE BENEFIT PLAN	9. EMPLOYEE BENEFIT PLAN In November 2006, the Company adopted a 401(k) plan (the “Plan”) covering all employees. Employees must be 21 years of age in order to participate in the Plan. Under the Plan, the Company has the option to make matching contributions. During the three months ended March 31, 2021 and 2020, the Company contributed $21 thousand and $19 thousand, respectively in matching cash contributions to employee 401(k) accounts.

COMMON STOCK

COMMON STOCK	3 Months Ended
	Mar. 31, 2021
COMMON STOCK.
COMMON STOCK	10. COMMON STOCK On January 21, 2020, the Company held its 2019 Annual Meeting of Stockholders (the “2019 Annual Meeting”). At the 2019 Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of authorized common stock from 25,000,000 to 500,000,000 (without giving effect to the 2020 Reverse Stock Split). On February 11, 2020, the Company effected the 2020 Reverse Stock Split and the number of shares of authorized common stock was reduced to 16,666,667. On August 4, 2020, the Company held its 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”). At the 2020 Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of authorized common stock from 16,666,667 to 50,000,000 shares. As of March 31, 2021, and December 31, 2020, 34,264,756 and 23,631,886 shares were issued and outstanding, respectively. In October 2020, the Company completed a registered public offering (the “October 2020 Offering”) in which it sold an aggregate of (i) 11,785,000 shares of common stock, (the “October 2020 Shares”) and Series A Warrants exercisable for an aggregate of 11,785,000 shares of the Company’s common stock (the “October 2020 Series A Warrants”) at a combined public offering price of $0.80 per share and associated warrant and (ii) pre-funded Series B warrants exercisable for an aggregate of 6,965,000 shares of common stock (the “October 2020 Series B Pre-funded Warrants”) and Series A Warrants exercisable for an aggregate of 6,965,000 shares of the Company’s common stock (also the “October 2020 Series A Warrants”) at a combined public offering price of $0.80 per pre-funded warrant and associated warrant. Each October 2020 Series A Warrant has an exercise price of $0.80 per share, is exercisable immediately and expires in October 2025. Each October 2020 Series B Pre-funded Warrant has an exercise price of $0.00001 per share, is exercisable immediately, and expires when exercised in full, subject to certain conditions. In connection with the October 2020 Offering, the Company issued, to designees of H.C. Wainwright & Co., LLC (“Wainwright”) the placement agent for the October 2020 Offering, warrants (the “October 2020 Placement Agent Warrants”) to purchase an aggregate of 1,218,750 shares of the Company’s common stock, which represents a number of shares of common stock equal to 6.5% of the aggregate number of shares of common stock and October 2020 Series B Pre-funded Warrants sold in the October 2020 Offering. The October 2020 Placement Agent Warrants have an exercise price of $1.00 per share, are immediately exercisable and expire in October 2025. The net proceeds to the Company, after deducting Wainwright's placement agent fees and other offering expenses payable by the Company, were approximately $13.5 million. The Company assessed whether the October 2020 Series A Warrants, October 2020 Series B Pre-funded Warrants and the October 2020 Placement Agent Warrants required accounting as derivatives and determined that they were (1) indexed to the Company’s own stock and (2) classified in stockholders’ equity in accordance with Accounting Standards Codification (“ASC”) Topic 815, Derivatives and Hedging. As such, the Company concluded that the October 2020 Series A Warrants, October 2020 Series B Pre-funded Warrants and the October 2020 Placement Agent Warrants meet the scope exception for determining whether the instruments require accounting as derivatives and accordingly are classified in stockholders’ equity. The fair value of the October 2020 Series A Warrants and October 2020 Placement Agent Warrants was estimated at $8.7 million and $551.3 thousand, respectively, using a Black-Scholes model with the following assumptions: expected volatility of 119.13%, risk free interest rate of 0.35%, expected life of 5 years and no dividends. The October 2020 Series B Pre-funded Warrants had an intrinsic value of approximately $5.6 million. There are no outstanding October 2020 Series B Pre-funded Warrants as of as of March 31, 2021. During the three months ended March 31, 2021 the Company issued an aggregate of 10,620,682 and 12,188 shares of common stock upon the exercise of certain of the October 2020 Series A Warrants and October 2020 Placement Agent Warrants, respectively, for aggregate proceeds of $8.5 million. In April 2020, the Company entered into a securities purchase agreement (the "April 2020 Purchase Agreement") with certain institutional investors (the "April 2020 Purchasers"), pursuant to which the Company agreed to sell and issue, in a registered direct offering, an aggregate of 1,715,240 of common stock, at a purchase price per share of $1.75 (the "April 2020 Shares"; the offering, the “April 2020 Registered Offering”). The April 2020 Shares were offered by the Company pursuant to a shelf registration statement on Form S-3, which was declared effective by the SEC on November 14, 2019 (File No. 333-234353) and a prospectus supplement thereunder. Pursuant to the April 2020 Purchase Agreement, in a concurrent private placement, the Company also issued to the April 2020 Purchasers warrants (the "April 2020 Series C Warrants") to purchase up to 1,715,240 shares of common stock (the "Private Placement" and together with the April 2020 Registered Offering, the "April 2020 Offerings"). The April 2020 Series C Warrants are exercisable immediately at an exercise price of $1.62 per share of common stock, subject to adjustment in certain circumstances, and expire on October 17, 2025. In connection with the April 2020 Offerings, the Company also issued to Wainwright, warrants to purchase an aggregate of 111,491 shares of the Company’s common stock (“April 2020 Placement Agent Warrants”) which represents a number of shares of common stock equal to 6.5% of the aggregate number of April 2020 Shares sold in the April 2020 Registered Offering, at an exercise price of $2.1875 per share with a term expiring on April 15, 2025. The net proceeds to the Company, after deducting Wainwright's placement agent fees and other offering expenses payable by the Company, were approximately $2.6 million. The Company assessed whether the April 2020 Series C Warrants, and the April 2020 Placement Agent Warrants required accounting as derivatives and determined that they were (1) indexed to the Company’s own stock and (2) classified in stockholders’ equity in accordance with ASC Topic 815, Derivatives and Hedging. As such, the Company concluded that the April 2020 Series C Warrants and the April 2020 Placement Agent Warrants meet the scope exception for determining whether the instruments require accounting as derivatives and accordingly are classified in stockholders’ equity. The fair value of the April 2020 Series C Warrants was estimated at $2.1 million, using a Black-Scholes model with the following assumptions: expected volatility of 115.84%, risk free interest rate of 0.40%, expected life of 5.5 years and no dividends. The fair value of the April 2020 Placement Agent Warrants was estimated at $128 thousand, using a Black-Scholes model with the following assumptions: expected volatility of 116.14%, risk free interest rate of 0.36%, expected life of 5 years and no dividends. The Company did not issue any shares as a result of either the April 2020 Series C Warrants or April 2020 Placement Agent Warrants exercise activity during the three months ended March 31, 2021. In March 2020, the Company completed a registered public offering (the “March 2020 Offering”) in which it sold an aggregate of (i) 955,613 shares of common stock (the “March 2020 Shares”) and Series A Warrants exercisable for an aggregate of 955,613 shares of the Company’s common stock (the “March 2020 Series A Warrants”) at a combined public offering price of $2.75 per share and associated warrant and (ii) pre-funded Series B warrants exercisable for an aggregate of 1,589,842 shares of common stock (the “March 2020 Series B Warrants”) and Series A Warrants exercisable for an aggregate of 1,589,842 shares of the Company’s common stock (also the “March 2020 Series A Warrants”) at a combined public offering price of $2.75 per pre-funded warrant and associated warrant. Each March 2020 Series A Warrant has an exercise price of $2.75 per share, is exercisable immediately and expires in March 2025. Each March 2020 Series B Warrant has an exercise price of $0.00001 per share, is exercisable immediately, and expires when exercised in full, subject to certain conditions. In connection with the March 2020 Offering, the Company issued, to Wainwright the placement agent for the March 2020 Offering, warrants to purchase an aggregate of 165,455 shares of the Company’s common stock (the “March 2020 Placement Agent Warrants”), which represents a number of shares of common stock equal to 6.5% of the aggregate number of shares of common stock and March 2020 Series B Warrants sold in the March 2020 Offering. The March 2020 Placement Agent Warrants have an exercise price of $3.4375 per share, are immediately exercisable and expire in March 2025. The net proceeds to the Company, after deducting Wainwright's placement agent fees and other offering expenses payable by the Company, were approximately $6.0 million. The Company assessed whether the March 2020 Series A Warrants, March 2020 Series B Warrants and the March 2020 Placement Agent Warrants required accounting as derivatives and determined that they were (1) indexed to the Company’s own stock and (2) classified in stockholders’ equity in accordance with ASC Topic 815, Derivatives and Hedging. As such, the Company concluded that the March 2020 Series A Warrants, March 2020 Series B Warrants and the March 2020 Placement Agent Warrants meet the scope exception for determining whether the instruments require accounting as derivatives and accordingly are classified in stockholders’ equity. The fair value of the March 2020 Series A warrants and March 2020 Placement Agent Warrants was estimated at $3.5 million and $218 thousand, respectively, using a Black-Scholes model with the following assumptions: expected volatility of 115.22%, risk free interest rate of 0.63%, expected life of 5 years and no dividends. The March 2020 Series B Warrants had an intrinsic value of approximately $4.4 million. During the three months ended March 31, 2020, the Company issued an aggregate of 1,016,537 shares of common stock upon the exercise of the March 2020 Series B warrants for an immaterial amount as they were substantially pre-funded. The Company did not issue any shares as a result of either the March 2020 Series A Warrant or March 2020 Placement Agent Warrants during the three months ended March 31, 2020. The Company did not issue any shares as a result of either the March 2020 Series A Warrant, March 2020 Series B Warrants or March 2020 Placement Agent Warrants during the three months ended March 31, 2021. During the three months ended March 31, 2020 the Company issued an aggregate of 40,975 shares of common stock upon the exercise of certain warrants issued in 2018 for aggregate proceeds of $286 thousand. During the three months ended March 31, 2021, there was no exercise activity related to any of the warrants that were issued in 2018 and 2019. During the three months ended March 31, 2020, as part of the adjustment to reflect the 2020 Reverse Stock Split, the Company issued an aggregate of 7,692 shares of common stock to account for the fractional roundup of shareholders. The Company did not issue any shares as a result of the vesting of restricted stock units during either of the three months ended March 31, 2021, and 2020.

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	3 Months Ended
	Mar. 31, 2021
SHARE-BASED COMPENSATION [Abstract]
SHARE-BASED COMPENSATION	11. STOCK-BASED COMPENSATION In 2007, the Company’s Board of Directors adopted, and the Company’s shareholders subsequently approved, the 2007 Employee, Director and Consultant Stock Plan (the “2007 Plan”). The 2007 Plan provided that the Company’s Board of Directors (or committees and/or executive officers delegated by the Board of Directors) could grant incentive and nonqualified stock options to the Company’s employees, officers, directors, consultants and advisors. On October 26, 2010, the Company’s Board of Directors adopted, and the Company’s shareholders subsequently approved, the 2010 Equity Incentive Plan (as subsequently amended, the “2010 Plan”). The 2010 Plan provided for grants of incentive stock options to employees, and nonqualified stock options and restricted common stock to employees, consultants, and non-employee directors of the Company. In April 2015, the Company’s Board of Directors adopted, and the Company’s shareholders subsequently approved, the 2015 Equity Incentive Plan (the “2015 Plan”). The 2015 Plan provides for grants of incentive stock options to employees, and nonqualified stock options, restricted common stock, restricted stock units (“RSUs”), and stock appreciation rights to employees, consultants, and non-employee directors of the Company. Upon approval of the 2015 Plan by the Company’s shareholders on June 16, 2015, the 2010 Plan was terminated and no additional shares or share awards have been subsequently granted under the 2010 Plan. In March 2019, the Company’s Board of Directors approved, and recommended to the Company’s shareholders for approval, an amendment to the 2015 Plan (the “2015 Plan Amendment”), and on January 21, 2020, the Company’s shareholders subsequently approved the 2015 Plan Amendment. The 2015 Plan Amendment increased the maximum number of shares reserved for issuance under the 2015 Plan by 26,667 shares to a total of 32,000 shares. In June 2020, the Company’s Board of Directors approved, and recommended to the Company’s shareholders for approval, another amendment to the 2015 Plan to increase the number of shares available for issuance by 400,000 shares, and on August 4, 2020, the Company’s shareholders subsequently approved that amendment. As of March 31, 2021, the total number of shares available to be issued under the 2015 Plan was 67,419 shares, consisting of (i) 5,333 shares initially authorized under the 2015 Plan shares, (ii) the shares that remained available for grant under the 2010 Plan at the time of its termination adjusted for cumulative cancellations, forfeitures and issuances from the 2010 Plan and 2015 Plan, (iii) the 26,667 shares approved for increase during the January 2020 shareholders meeting and, (iv) the 400,000 shares approved for increase during the 2020 Annual Meeting. Options issued under the 2007 Plan, 2010 Plan, and 2015 Plan (collectively, the “Plans”) are exercisable for up to 10 years from the date of issuance. Stock-based compensation For the three month periods ended March 31, 2021 and 2020, Stock-based compensation recognized was classified in the consolidated statements of operations as follows: Three Months Ended March 31, (In thousands) 2021 2020 Research and development $ 3 $ 20 General and administrative 49 50 Total $ 52 $ 70 The fair value of each option award is estimated on the date of grant using the Black ‑ Scholes option pricing model, which uses the following assumptions; (i) Risk-free interest rate, (ii) Expected dividend yield, (iii) Expected term and (iv) Expected volatility. The Company uses historical data, as well as subsequent events occurring prior to the issuance of the financial statements, to estimate option exercises within the valuation model. The expected term of options granted under the Plans, all of which qualify as “plain vanilla,” is based on the average of the contractual term (10 years) and the vesting period (generally, 48 months). For non‑employee options, the expected term is the contractual term. The risk‑free rate is based on the yield of a U.S. Treasury security with a term consistent with the option. The impact of forfeitures on compensation expense is recorded as they occur. The Company grants RSUs and restricted stock awards (“RSAs”), collectively referred to as restricted securities under the 2015 Equity Incentive Plan. These restricted securities generally vest over a three-year period, contingent on the recipient’s continued employment. Prior to vesting, all RSAs have the right to vote and receive dividends under the 2015 Equity Incentive Plan; however, the Company’s form of Restricted Stock Agreement provides that the payment of dividends on unvested RSAs shall be deferred until such time as the shares vest. The grant date fair value of these awards is based on the fair market value of our common stock on the date of grant. The Company did not grant any awards during the three months ended March 31, 2020. The assumptions used principally in determining the fair value of options granted during the three months ended March 31, 2021 were as follows: March 31, 2021 Risk-free interest rate 1.03% Expected dividend yield 0% Expected term (employee grants) 5.70 Expected volatility 117.34% Stock options A summary of option activity as of March 31, 2021 and changes for the three month period then ended are presented below: Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Options Shares Price Term in Years Value Outstanding as of December 31, 2020 4,169 $ 1,054.01 $ — Granted 360,000 $ 1.10 Cancelled/Forfeited (147) $ 6,324.03 Outstanding as of March 31, 2021 364,022 $ 10.61 9.93 $ — Vested and Exercisable as of March 31, 2021 2,986 $ 1,121.83 6.90 $ — Vested and expected to vest as of March 31, 2021 364,022 $ 10.61 9.93 $ — The weighted-average grant-date fair value of stock options granted during the three months ended March 31, 2021 was $0.93. The total fair value of options that vested in the three months ended March 31, 2021 and 2020 was $53 thousand and $56 thousand, respectively. For the three month periods ended March 31, 2021 and 2020, the Company recorded stock-based compensation expense of $28 thousand and $43 thousand, respectively related to stock options. As of March 31, 2021, total unrecognized compensation expense related to non-vested share-based option compensation arrangements amounted to $367 thousand and is estimated to be recognized over a period of 1.63 years. Restricted Securities The following table summarizes the restricted securities activity under the 2015 Plan during the three month period ended March 31, 2021: Weighted-Average Restricted Securities Number of Grants Grant Date Fair Value Unvested balance as of December 31, 2020 6,402 $ 25.67 Vested — $ — Forfeited — $ — Unvested balance as of March 31, 2021 6,402 $ 25.67 For the three month periods ended March 31, 2021, and 2020, the Company recorded stock-based compensation expense of $24 thousand and $27 thousand, respectively, related to the time-based restricted securities As of March 31, 2021, total unrecognized compensation expense related to non-vested restricted securities amounted to $96 thousand which the Company expects to recognize over a remaining weighted-average of 1.11 years. All the restricted securities that remain unvested and outstanding as of March 31, 2021 are subject to time-based vesting.

WARRANTS

WARRANTS	3 Months Ended
	Mar. 31, 2021
WARRANTS
WARRANTS	12. WARRANTS The following table presents information about warrants to purchase common stock issued and outstanding as of March 31, 2021: Number of Exercise Price as of Year Issued Defined Name Classification Warrants March 31, 2021 Date of Expiration 2014 2014 Warrants Equity 11 $ 352.50 5/9/2021 2018 2018 Series A Warrants Equity 211,921 $ 6.98 6/25/2023 2019 2019 Placement Agent Warrants Equity 15,168 $ 4.50 11/21/2024 2020 March 2020 Series A Warrants Equity 2,545,455 $ 2.75 3/10/2025 2020 March 2020 Placement Agent Warrants Equity 165,455 $ 3.4375 3/5/2025 2020 March 2020 Series B Warrants Equity 12,728 $ 0.00001 Until Fully Exercised 2020 April 2020 Series C Warrants Equity 1,680,240 $ 1.62 10/17/2025 2020 April 2020 Placement Agent Warrants Equity 111,491 $ 2.1875 4/15/2025 2020 October 2020 Placement Agent Warrants Equity 1,206,562 $ 1.00 10/22/2025 2020 October 2020 Series A Warrants Equity 8,129,318 $ 0.80 10/27/2025 Total 14,078,349 Weighted average exercise price $ 1.41 Weighted average life in years 4.41

NET LOSS PER COMMON SHARE

NET LOSS PER COMMON SHARE	3 Months Ended
	Mar. 31, 2021
NET LOSS PER COMMON SHARE
NET LOSS PER COMMON SHARE	13. NET LOSS PER COMMON SHARE Basic and diluted net loss per share of common stock has been computed by dividing net loss by the weighted average number of shares outstanding during the period. Diluted net loss per share of common stock is computed by dividing net income by the weighted average number of shares outstanding plus the dilutive effect, if any, of outstanding stock options, warrants and convertible securities. In a net loss period, options, warrants, unvested restricted securities and convertible securities are anti-dilutive and, therefore, excluded from diluted loss per share calculations. For the three months ended March 31, 2021 and 2020, the following potentially dilutive securities were not included in the computation of net loss per share because the effect would be anti-dilutive: March 31, 2021 2020 Warrants 14,078,349 3,514,180 Stock options 364,022 4,187 Unvested RSUs 100 200 Unvested RSAs 6,302 6,886 Total potentially dilutive securities 14,448,773 3,525,453

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2021
NATURE OF OPERATIONS AND GOING CONCERN, BASIS OF PRESENTATION AND RECENT ACCOUNTING PRONOUNCEMENTS
Going Concern	Going Concern The Company’s consolidated financial statements as of March 31, 2021 were prepared under the assumption that the Company will continue as a going concern. As of March 31, 2021, the Company had unrestricted cash and cash equivalents of $24.8 million. Given the Company’s current development plans, the Company estimates cash resources will be sufficient to fund its operations, through the second quarter of 2023. The Company’s ability to continue as a going concern depends on its ability to obtain additional equity or debt financing, attain further operating efficiencies, manage expenditures, and, ultimately, to generate revenue. If the Company is unable to continue as a going concern, it may have to liquidate its assets and may receive less than the value at which those assets are carried on its audited financial statements, and it is likely that investors will lose all or part of their investment.
Reverse Stock Split	Reverse Stock Split On February 11, 2020, the Company effected a reverse stock split of its common stock, par value $0.00001 per share, at a ratio of 1-for-30 (the “2020 Reverse Stock Split”). As a result of the 2020 Reverse Stock Split, (i) every 30 shares of the issued and outstanding common stock were automatically converted into one newly issued and outstanding share of common stock, without any change in the par value per share; (ii) the number of shares of common stock into which each outstanding warrant or option to purchase common stock is exercisable was proportionally decreased, and (iii) the number of authorized shares of common stock outstanding was proportionally decreased. Shares of common stock underlying outstanding stock options and other equity instruments convertible into common stock were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. All of the Company’s historical share and per share information related to issued and outstanding common stock and outstanding options and warrants exercisable for common stock in these consolidated financial statements were adjusted, on a retroactive basis to reflect the 2020 Reverse Stock Split.
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) consistent with those applied in, and should be read in conjunction with, the Company’s audited consolidated financial statements and related footnotes for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K as filed with the United States Securities and Exchange Commission (“SEC”) on March 1, 2021. The unaudited consolidated financial statements reflect all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the Company’s financial position as of March 31, 2021 and its results of operations and cash flows for the interim periods presented, and are not necessarily indicative of results for subsequent interim periods or for the full year. The interim consolidated financial statements do not include all of the information and footnotes required by U.S. GAAP for complete financial statements, as allowed by the relevant SEC rules and regulations; however, the Company believes that its disclosures are adequate to ensure that the information presented is not misleading.

CASH AND CASH EQUIVALENTS (Tabl

CASH AND CASH EQUIVALENTS (Tables)	3 Months Ended
	Mar. 31, 2021
CASH AND CASH EQUIVALENTS
Schedule of cash and cash equivalents	March 31, December 31, (In thousands) 2021 2020 Cash $ 52 $ (13) Money market funds 24,715 19,506 Total cash and cash equivalents $ 24,767 $ 19,493

FAIR VALUES OF ASSETS AND LIA_2

FAIR VALUES OF ASSETS AND LIABILITIES (Tables)	3 Months Ended
	Mar. 31, 2021
FAIR VALUES OF ASSETS AND LIABILITIES
Summary of assets and liabilities measured at fair value on a recurring basis	As of March 31, 2021 (In thousands) Level 1 Level 2 Level 3 Fair Value Cash equivalents $ 24,715 $ — $ — $ 24,715 As of December 31, 2020 (In thousands) Level 1 Level 2 Level 3 Fair Value Cash equivalents $ 19,506 $ — $ — $ 19,506

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	3 Months Ended
	Mar. 31, 2021
COMMITMENTS AND CONTINGENCIES
Schedule of lease cost	Three Months Ended March 31, Lease cost (In thousands) 2021 2020 Operating lease cost $ 91 $ 91 Short-term lease cost 2 8 Variable lease cost 27 25 Total lease cost $ 120 $ 124 Other information (In thousands) Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from short term leases $ 2 $ 8 Operating cash flows from operating leases 95 93 Total cash paid for leases $ 97 $ 101 Weighted-average remaining lease term - operating leases 2.6 Years 3.6 Years Weighted-average discount rate - operating leases
Schedule of maturities of lease liabilities	Leases (In thousands) As of March 31, 2021 2021(excluding the 3 months ended March 31, 2021) $ 290 2022 398 2023 339 Total lease payments 1,027 Less: imputed interest (86) Present value of lease liabilities $ 941
Schedule of balance sheet information	Leases (In thousands) Classification March 31, 2021 December 31, 2020 Assets Lease asset, net Operating $ 853 $ 928 Total lease assets $ 853 $ 928 Liabilities Current Operating $ 336 $ 327 Non-current Operating 605 693 Total lease liabilities $ 941 $ 1,020

FIXED ASSETS (Tables)

FIXED ASSETS (Tables)	3 Months Ended
	Mar. 31, 2021
FIXED ASSETS
Schedule of property and equipment, net	March 31, December 31, (In thousands) 2021 2020 Computer software and hardware $ 40 $ 40 Research and lab equipment 520 520 Leasehold improvements 66 66 Property and equipment 626 626 Less accumulated depreciation (550) (541) Property and equipment, net $ 76 $ 85

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2021
INTANGIBLE ASSETS
Summary of intangible assets	March 31, December 31, (In thousands) 2021 2020 Patent licensing fee $ 200 $ 200 Accumulated amortization (196) (191) Other assets $ 4 $ 9

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	3 Months Ended
	Mar. 31, 2021
ACCRUED EXPENSES.
Summary of accrued expenses	March 31, December 31, (In thousands) 2021 2020 Compensation $ 237 $ 996 Clinical 138 5 Legal 21 17 Other accrued expenses 103 146 Total accrued expenses $ 499 $ 1,164

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	3 Months Ended
	Mar. 31, 2021
SHARE-BASED COMPENSATION [Abstract]
Schedule of stock-based compensation	Stock-based compensation recognized was classified in the consolidated statements of operations as follows: Three Months Ended March 31, (In thousands) 2021 2020 Research and development $ 3 $ 20 General and administrative 49 50 Total $ 52 $ 70
Schedule of assumptions used principally in determining the fair value of options granted	The assumptions used principally in determining the fair value of options granted during the three months ended March 31, 2021 were as follows: March 31, 2021 Risk-free interest rate 1.03% Expected dividend yield 0% Expected term (employee grants) 5.70 Expected volatility 117.34%
Summary of option activity	Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Options Shares Price Term in Years Value Outstanding as of December 31, 2020 4,169 $ 1,054.01 $ — Granted 360,000 $ 1.10 Cancelled/Forfeited (147) $ 6,324.03 Outstanding as of March 31, 2021 364,022 $ 10.61 9.93 $ — Vested and Exercisable as of March 31, 2021 2,986 $ 1,121.83 6.90 $ — Vested and expected to vest as of March 31, 2021 364,022 $ 10.61 9.93 $ —
Summary of restricted stock unit activity	Weighted-Average Restricted Securities Number of Grants Grant Date Fair Value Unvested balance as of December 31, 2020 6,402 $ 25.67 Vested — $ — Forfeited — $ — Unvested balance as of March 31, 2021 6,402 $ 25.67

WARRANTS (Tables)

WARRANTS (Tables)	3 Months Ended
	Mar. 31, 2021
WARRANTS
Schedule of information about warrants to purchase common stock issued and outstanding	The following table presents information about warrants to purchase common stock issued and outstanding as of March 31, 2021: Number of Exercise Price as of Year Issued Defined Name Classification Warrants March 31, 2021 Date of Expiration 2014 2014 Warrants Equity 11 $ 352.50 5/9/2021 2018 2018 Series A Warrants Equity 211,921 $ 6.98 6/25/2023 2019 2019 Placement Agent Warrants Equity 15,168 $ 4.50 11/21/2024 2020 March 2020 Series A Warrants Equity 2,545,455 $ 2.75 3/10/2025 2020 March 2020 Placement Agent Warrants Equity 165,455 $ 3.4375 3/5/2025 2020 March 2020 Series B Warrants Equity 12,728 $ 0.00001 Until Fully Exercised 2020 April 2020 Series C Warrants Equity 1,680,240 $ 1.62 10/17/2025 2020 April 2020 Placement Agent Warrants Equity 111,491 $ 2.1875 4/15/2025 2020 October 2020 Placement Agent Warrants Equity 1,206,562 $ 1.00 10/22/2025 2020 October 2020 Series A Warrants Equity 8,129,318 $ 0.80 10/27/2025 Total 14,078,349 Weighted average exercise price $ 1.41 Weighted average life in years 4.41

NET LOSS PER COMMON SHARE (Tabl

NET LOSS PER COMMON SHARE (Tables)	3 Months Ended
	Mar. 31, 2021
NET LOSS PER COMMON SHARE
Schedule of potentially dilutive securities not included in the computation of net loss per share because effect would be anti-dilutive	March 31, 2021 2020 Warrants 14,078,349 3,514,180 Stock options 364,022 4,187 Unvested RSUs 100 200 Unvested RSAs 6,302 6,886 Total potentially dilutive securities 14,448,773 3,525,453

NATURE OF OPERATIONS AND GOIN_2

NATURE OF OPERATIONS AND GOING CONCERN, BASIS OF PRESENTATION AND RECENT ACCOUNTING PRONOUNCEMENTS Reverse Stock Split (Details) $ / shares in Units, $ in Thousands	Feb. 11, 2020$ / shares	Mar. 31, 2021USD ($)$ / shares	Mar. 31, 2020shares	Dec. 31, 2020USD ($)$ / shares
NATURE OF OPERATIONS AND GOING CONCERN, BASIS OF PRESENTATION AND RECENT ACCOUNTING PRONOUNCEMENTS
Cash and cash equivalents | $		$ 24,767		$ 19,493
Common stock, par value (in dollars per share) | $ / shares	$ 0.00001	$ 0.00001		$ 0.00001
Reverse stock split ratio	0.0333		0.03333
Stock issued during period, shares, reverse stock splits | shares			7,692
Reverse stock split		On February 11, 2020, the Company effected a reverse stock split of its common stock, par value $0.00001 per share, at a ratio of 1-for-30 (the "2020 Reverse Stock Split"). As a result of the 2020 Reverse Stock Split, (i) every 30 shares of the issued and outstanding common stock were automatically converted into one newly issued and outstanding share of common stock, without any change in the par value per share; (ii) the number of shares of common stock into which each outstanding warrant or option to purchase common stock is exercisable was proportionally decreased, and (iii) the number of authorized shares of common stock outstanding was proportionally decreased. Shares of common stock underlying outstanding stock options and other equity instruments convertible into common stock were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.
Going concern		false

CASH AND CASH EQUIVALENTS - CAS

CASH AND CASH EQUIVALENTS - CASH AND CASH EQUIVALENTS (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
CASH AND CASH EQUIVALENTS
Cash	$ 52	$ (13)
Money market funds	24,715	19,506
Total cash and cash equivalents	$ 24,767	$ 19,493

RESTRICTED CASH (Details)

RESTRICTED CASH (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Restricted cash
Restricted cash	$ 110	$ 110
Security deposit related to credit card account
Restricted cash
Restricted cash	50	50
Standby letter of credit
Restricted cash
Restricted cash	$ 60	$ 60

FAIR VALUES OF ASSETS AND LIA_3

FAIR VALUES OF ASSETS AND LIABILITIES (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Assets and liabilities measured at fair value on a recurring basis
Transfers from level 1 to level 2	$ 0	$ 0
Transfers from level 2 to level 1	0	0
Transfers into level 3	0	$ 0
Recurring basis
Assets and liabilities measured at fair value on a recurring basis
Cash equivalents	24,715		$ 19,506
Recurring basis | Level 1
Assets and liabilities measured at fair value on a recurring basis
Cash equivalents	$ 24,715		$ 19,506

COMMITMENTS AND CONTINGENCIES,

COMMITMENTS AND CONTINGENCIES, LEASES (Details) - Cambridge Lease $ in Thousands	Nov. 01, 2018USD ($)	May 03, 2018USD ($)ft²
Lessee, Lease, Description [Line Items]
Standby letter of credit | $	$ 60	$ 40
Sublease
Lessee, Lease, Description [Line Items]
Lease space (in square feet) | ft²		5,104

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES, LEASE EXPENSE (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Lease expense
Operating lease cost	$ 91	$ 91
Short-term lease cost	2	8
Variable lease cost	27	25
Total lease cost	$ 120	$ 124

COMMITMENTS AND CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES, LEASE OTHER INFORMATION (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
COMMITMENTS AND CONTINGENCIES
Operating cash flows from short term leases	$ 2	$ 8
Operating cash flows from operating leases	95	93
Total cash paid for leases	$ 97	$ 101
Weighted-average remaining lease term - operating leases (years)	2 years 7 months 6 days	3 years 7 months 6 days
Weighted-average discount rate - operating leases	7.00%	7.00%

COMMITMENTS AND CONTINGENCIES_4

COMMITMENTS AND CONTINGENCIES, MATURITIES OF LEASE LIABILITIES (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Maturities of lease liabilities
2021(excluding the 3 months ended March 31, 2021)	$ 290
2022	398
2023	339
Total lease payments	1,027
Less: imputed interest	(86)
Present value of lease liabilities	$ 941	$ 1,020

COMMITMENTS AND CONTINGENCIES_5

COMMITMENTS AND CONTINGENCIES, LEASE CLASSIFICATION (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
COMMITMENTS AND CONTINGENCIES
Operating Lease, Right-of-Use Asset	$ 853	$ 928
Financial position	Total lease assets
Total lease assets	$ 853	928
Operating Liabilities - Current	$ 336	327
Financial position	Operating Liabilities - Current
Operating Liabilities - Non Current	$ 605	693
Financial position	Operating Liabilities - Non Current
Total Operating Liabilities	$ 941	$ 1,020
Financial position	us-gaap:OperatingLeaseLiabilityCurrent us-gaap:OperatingLeaseLiabilityNoncurrent

COMMITMENTS AND CONTINGENCIES_6

COMMITMENTS AND CONTINGENCIES, COMPENSATION (Details) $ in Millions	Mar. 31, 2021USD ($)
Research and Development Arrangement
Compensation Arrangement
Commitments	$ 4

FIXED ASSETS, SCHEDULE (Details

FIXED ASSETS, SCHEDULE (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Property and equipment
Property and equipment	$ 626	$ 626
Less accumulated depreciation	(550)	(541)
Property and equipment, net	76	85
Computer software and hardware
Property and equipment
Property and equipment	40	40
Research and lab equipment
Property and equipment
Property and equipment	520	520
Leasehold improvements
Property and equipment
Property and equipment	$ 66	$ 66

FIXED ASSETS (Details)

FIXED ASSETS (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Depreciation
Depreciation expense	$ 9	$ 7

INTANGIBLE ASSETS (Details)

INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020	Jul. 31, 2007
BCH License [Member]
Intangible assets
Useful life	15 years
Intangible assets - gross	$ 200	$ 200	$ 75
Patent licensing fee
Intangible assets
Useful life	15 years
Intangible assets - gross	$ 200	200
Accumulated amortization	(196)	(191)
Intangible assets, net	$ 4	$ 9

INTANGIBLE ASSETS, AMORTIZATION

INTANGIBLE ASSETS, AMORTIZATION (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Amortization
Amortization expense	$ 5	$ 4

ACCRUED EXPENSES (Details)

ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
ACCRUED EXPENSES.
Compensation	$ 237	$ 996
Clinical	138	5
Legal	21	17
Other accrued expenses	103	146
Total accrued expenses	$ 499	$ 1,164

EMPLOYEE BENEFIT PLAN (Details)

EMPLOYEE BENEFIT PLAN (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Employee benefit plan disclosures
Eligibility criteria for participation in the Plan	21 years
401(k)
Employee benefit plan disclosures
Employer Matching Contribution	$ 21	$ 19

COMMON STOCK, AUTHORIZED (Detai

COMMON STOCK, AUTHORIZED (Details) - shares	Mar. 31, 2021	Dec. 31, 2020	Aug. 04, 2020	Aug. 03, 2020	Feb. 11, 2020	Jan. 21, 2020	May 31, 2018
Common stock, number of shares, par value and other disclosures
Common stock, authorized	50,000,000	50,000,000	50,000,000	16,666,667	16,666,667	500,000,000	25,000,000
Common stock, issued	34,264,756	23,631,886
Common stock, outstanding	34,264,756	23,631,886

COMMON STOCK, TRANSACTIONS (Det

COMMON STOCK, TRANSACTIONS (Details)	1 Months Ended				3 Months Ended
	Oct. 31, 2020USD ($)$ / sharesshares	Apr. 30, 2020USD ($)$ / sharesshares	Mar. 31, 2020USD ($)$ / sharesshares	Jan. 31, 2020shares	Mar. 31, 2021USD ($)Y$ / sharesshares	Mar. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2020$ / shares	Feb. 11, 2020$ / shares
Common stock disclosure
Common stock, par value (in dollars per share) | $ / shares					$ 0.00001		$ 0.00001	$ 0.00001
Proceeds from issuance of common stock and warrants, net of commissions and issuance costs						$ 6,035,000
Proceeds from exercise of warrants					$ 8,509,000	286,000
Number of Warrants | shares					14,078,349
April 2020 Shares [Member]
Common stock disclosure
Number of shares issued (in shares) | shares		1,715,240
Equity issuance (in price per unit) | $ / shares		$ 1.75
Proceeds from issuance of common stock		$ 2,600,000
Expected volatility
Common stock disclosure
Fair value assumptions					115.22
Risk-free interest rate
Common stock disclosure
Fair value assumptions					0.63
Contractual term
Common stock disclosure
Fair value assumptions | Y					5
Expected dividend yield
Common stock disclosure
Fair value assumptions					0
April 2020 Warrants
Common stock disclosure
Number of warrants to purchase aggregate number of shares | shares		1,715,240
Exercise price (in dollars per unit) | $ / shares		$ 1.62
Fair value of warrants		$ 2,100,000
Shares issued on exercise of warrants | shares					0
April 2020 Warrants | Expected volatility
Common stock disclosure
Fair value assumptions		115.84
April 2020 Warrants | Risk-free interest rate
Common stock disclosure
Fair value assumptions		0.40
April 2020 Warrants | Contractual term
Common stock disclosure
Warrant expiration term (in years)		5 years 6 months
April 2020 Warrants | Expected dividend yield
Common stock disclosure
Fair value assumptions		0
2018 Warrants {Member]
Common stock disclosure
Exercise price (in dollars per unit) | $ / shares					$ 6.98
Proceeds from exercise of warrants						$ 286,000
Warrants Exercised					$ 0
Number of Warrants | shares					211,921
Shares issued on exercise of warrants | shares						40,975
Series B Warrants 2020 [Member]
Common stock disclosure
Exercise price (in dollars per unit) | $ / shares			$ 0.00001			$ 0.00001
Intrinsic value					$ 4,400,000
Number of Warrants | shares			1,589,842			1,589,842
Shares issued on exercise of warrants | shares				1,016,537	0
Series A Warrants [Member]
Common stock disclosure
Exercise price (in dollars per unit) | $ / shares			$ 2.75			$ 2.75
Fair value of warrants					$ 3,500,000
Number of Warrants | shares			1,589,842			1,589,842
Shares issued on exercise of warrants | shares				0		0
Wainwright 2020 Placement Agent Warrants [Member]
Common stock disclosure
Number of warrants to purchase aggregate number of shares | shares		111,491
Exercise price (in dollars per unit) | $ / shares		$ 2.1875
Proceeds from issuance of common stock and warrants, net of commissions and issuance costs	$ 13,500,000
Fair value of warrants		$ 128,000			$ 218,000
Wainwright 2020 Placement Agent Warrants [Member] | Expected volatility
Common stock disclosure
Fair value assumptions		116.14
Wainwright 2020 Placement Agent Warrants [Member] | Risk-free interest rate
Common stock disclosure
Fair value assumptions		0.36
Wainwright 2020 Placement Agent Warrants [Member] | Contractual term
Common stock disclosure
Fair value assumptions		5
Wainwright 2020 Placement Agent Warrants [Member] | Expected dividend yield
Common stock disclosure
Fair value assumptions		0
Placement Agent Warrants
Common stock disclosure
Percentage of aggregate number of shares available			6.50%
Exercise price (in dollars per unit) | $ / shares			$ 3.4375		$ 1	$ 3.4375
Number of Warrants | shares			165,455		1,206,562	165,455
Shares issued on exercise of warrants | shares				0	12,188	0
Series B Prefunded Warrants October 2020
Common stock disclosure
Proceeds from exercise of warrants					$ 8,500,000
Number of Warrants | shares					0
Shares issued on exercise of warrants | shares					10,620,682
March 2020 Series A Warrants
Common stock disclosure
Number of shares issued (in shares) | shares			955,613
Common Stock
Common stock disclosure
Number of shares issued (in shares) | shares						955,613
Underwritten Public Offering March 2020 [Member]
Common stock disclosure
Number of shares issued (in shares) | shares			955,613
Underwritten Public Offering March 2020 [Member] | Common Stock
Common stock disclosure
Equity issuance (in price per unit) | $ / shares			$ 2.75			$ 2.75
Wainwright 2020 Placement Agent Warrants [Member]
Common stock disclosure
Percentage of warrants issued as a percentage of the warrants issued to the investors		6.50%
Proceeds from issuance of common stock and warrants, net of commissions and issuance costs			$ 6,000,000
October 2020 Offering [Member]
Common stock disclosure
Number of shares issued (in shares) | shares	11,785,000
Equity issuance (in price per unit) | $ / shares	$ 0.80
Fair value of warrants	$ 8,700,000
October 2020 Offering [Member] | Expected volatility
Common stock disclosure
Fair value assumptions	119.13
October 2020 Offering [Member] | Risk-free interest rate
Common stock disclosure
Fair value assumptions	0.35
October 2020 Offering [Member] | Contractual term
Common stock disclosure
Warrant expiration term (in years)	5 years
October 2020 Offering [Member] | Expected dividend yield
Common stock disclosure
Fair value assumptions	0
October 2020 Offering [Member] | Series A Warrants [Member]
Common stock disclosure
Equity issuance (in price per unit) | $ / shares	$ 0.80
Number of warrants to purchase aggregate number of shares | shares	11,785,000
October 2020 Offering [Member] | Wainwright 2020 Placement Agent Warrants [Member]
Common stock disclosure
Percentage of shares purchased by placement agent	6.50%
Number of warrants to purchase aggregate number of shares | shares	1,218,750
Exercise price (in dollars per unit) | $ / shares	$ 1
October 2020 Offering [Member] | Series A Prefunded Warrants October 2020
Common stock disclosure
Number of shares issued (in shares) | shares	6,965,000
Equity issuance (in price per unit) | $ / shares	$ 0.80
Fair value of warrants	$ 551,300
October 2020 Offering [Member] | Series B Prefunded Warrants October 2020
Common stock disclosure
Number of warrants to purchase aggregate number of shares | shares	6,965,000
Exercise price (in dollars per unit) | $ / shares	$ 0.00001
Fair value of warrants	$ 5,600,000

COMMON STOCK, TRANSACTIONS OTHE

COMMON STOCK, TRANSACTIONS OTHER (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Common stock disclosure
Stock issued during period, shares, reverse stock splits		7,692
Issuance of stock upon vesting of restricted stock units (in shares)	0	0
Proceeds from exercise of warrants	$ 8,509	$ 286
2018 Warrants {Member]
Common stock disclosure
Proceeds from exercise of warrants		$ 286

SHARE-BASED COMPENSATION (Detai

SHARE-BASED COMPENSATION (Details) - USD ($) $ in Thousands	Aug. 04, 2020	Jan. 31, 2020	Jan. 31, 2020	Jun. 30, 2015	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2015	Dec. 31, 2020	Apr. 30, 2015
Stock options
Expected term					10 years
Vesting period					48 months
Stock-based compensation (in dollars)					$ 52	$ 70
2010 Plan
Stock options
Granted (in shares)				0	0		0	0
Expected term					10 years
2015 Plan
Stock options
Shares available for future grants					67,419
Shares authorized for issuance									5,333
Expected term					10 years
Increase in shares of common stock reserved for issuance (in shares)	400,000		26,667
2015 Plan Amendment [Member]
Stock options
Shares authorized for issuance		32,000	32,000
Increase in shares of common stock reserved for issuance (in shares)	400,000	26,667
2007 Plan
Stock options
Expected term					10 years

SHARE-BASED COMPENSATION, SHARE

SHARE-BASED COMPENSATION, SHARE-BASED COMPENSATION (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Stock options
Stock-based compensation (in dollars)	$ 52	$ 70
Expected term	10 years
Vesting period	48 months
Research and development
Stock options
Stock-based compensation (in dollars)	$ 3	20
General and administrative
Stock options
Stock-based compensation (in dollars)	49	50
Stock Options
Stock options
Stock-based compensation (in dollars)	28	43
Restricted Securities
Stock options
Stock-based compensation (in dollars)	$ 24	$ 27
Vesting period	3 years

SHARE-BASED COMPENSATION, ASSUM

SHARE-BASED COMPENSATION, ASSUMPTIONS USED IN DETERMINING THE FAIR VALUE (Details) - Stock Options	3 Months Ended
	Mar. 31, 2021
Assumptions used principally in determining the fair value of options granted
Risk-free interest rate (as a percent)	1.03%
Expected dividend yield (as a percent)	0.00%
Expected term (employee grants)	5 years 8 months 12 days
Expected volatility (as a percent)	117.34%

SHARE-BASED COMPENSATION, SUMMA

SHARE-BASED COMPENSATION, SUMMARY OF OPTION ACTIVITY - (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Stock Option
Stock-based compensation (in dollars)	$ 52	$ 70
Stock Options
Summary of option activity - Shares
Outstanding at the beginning of year (in shares)	4,169
Granted (in shares)	360,000
Cancelled/Forfeited (in shares)	(147)
Outstanding at the end of period (in shares)	364,022		4,169
Vested and expected to vest at the end of period (in shares)	364,022
Vested and Exercisable at September 30, 2020	2,986
Summary of option activity - Weighted Average Exercise Price
Outstanding at the beginning of year (in dollars per shares)	$ 1,054.01
Granted (in dollars per shares)	1.10
Cancelled/Forfeited (in dollars per shares)	6,324.03
Outstanding at the end of period (in dollars per shares)	10.61		$ 1,054.01
Vested and Exercisable at September 30, 2020	1,121.83
Vested and expected to vest at the end of period (in dollars per share)	$ 10.61
Option activity disclosures
Weighted Average Remaining Contractual Term - Outstanding	9 years 11 months 5 days		7 years 2 months 5 days
Weighted Average Remaining Contractual Term - Vested and Exercisable	6 years 10 months 24 days
Stock Option
Weighted average grant-date fair value of options granted	$ 0.93
Total fair value of options vested	$ 53	56
Stock-based compensation (in dollars)	28	$ 43
Total unrecognized compensation expense	$ 367
Period for unrecognized compensation expense is estimated to be recognized	1 year 7 months 17 days

SHARE-BASED COMPENSATION, RESTR

SHARE-BASED COMPENSATION, RESTRICTED STOCK (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based compensation
Stock-based compensation (in dollars)	$ 52	$ 70
Restricted Securities
Number of Grants
Unvested balance at	6,402
Unvested balance at	6,402
Weighted-Average Grant Date Fair Value
Unvested balance at (in dollars per share)	$ 25.67
Unvested balance at (in dollars per share)	$ 25.67
Share-based compensation
Stock-based compensation (in dollars)	$ 24	$ 27
Unrecognized compensation
Total unrecognized compensation expense	$ 96
Period for unrecognized compensation expense is estimated to be recognized	1 year 1 month 10 days

WARRANTS (Details)

WARRANTS (Details) - $ / shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Warrants to purchase common stock issued and outstanding
Number of Warrants	14,078,349
Weighted average exercise price	$ 1.41
Weighted average life in years	4 years 4 months 28 days
Warrants 2014 [Member]
Warrants to purchase common stock issued and outstanding
Warrants Issued Year	2014
Number of Warrants	11
Warrant Exercise Price	$ 352.50
Expiration date	May 9, 2021
2018 Warrants {Member]
Warrants to purchase common stock issued and outstanding
Warrants Issued Year	2018
Number of Warrants	211,921
Warrant Exercise Price	$ 6.98
Expiration date	Jun. 25, 2023
Warrants 2019 [Member]
Warrants to purchase common stock issued and outstanding
Warrants Issued Year	2019
Number of Warrants	15,168
Warrant Exercise Price	$ 4.50
Expiration date	Nov. 21, 2024
Warrants 2020, First [Member]
Warrants to purchase common stock issued and outstanding
Warrants Issued Year	2020
Number of Warrants	2,545,455
Warrant Exercise Price	$ 2.75
Expiration date	Mar. 10, 2025
Warrants 2020, Second [Member]
Warrants to purchase common stock issued and outstanding
Warrants Issued Year	2020
Number of Warrants	165,455
Warrant Exercise Price	$ 3.4375
Expiration date	Mar. 5, 2025
Warrants 2020, Third [Member]
Warrants to purchase common stock issued and outstanding
Warrants Issued Year	2020
Number of Warrants	12,728
Warrant Exercise Price	$ 0.00001
Warrants 2020, Fourth [Member]
Warrants to purchase common stock issued and outstanding
Warrants Issued Year	2020
Number of Warrants	1,680,240
Warrant Exercise Price	$ 1.62
Expiration date	Oct. 17, 2025
Warrants 2020, Fifth [Member]
Warrants to purchase common stock issued and outstanding
Warrants Issued Year	2020
Number of Warrants	111,491
Warrant Exercise Price	$ 2.1875
Expiration date	Apr. 15, 2025
Placement Agent Warrants
Warrants to purchase common stock issued and outstanding
Warrants Issued Year	2020
Number of Warrants	1,206,562	165,455
Warrant Exercise Price	$ 1	$ 3.4375
Expiration date	Oct. 22, 2025
October 2020 Offering [Member]
Warrants to purchase common stock issued and outstanding
Warrants Issued Year	2020
Number of Warrants	8,129,318
Warrant Exercise Price	$ 0.80
Expiration date	Oct. 27, 2025

NET LOSS PER COMMON SHARE (Deta

NET LOSS PER COMMON SHARE (Details) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Anti-dilutive
Total potentially dilutive securities (in shares)	14,448,773	3,525,453
Warrants.
Anti-dilutive
Total potentially dilutive securities (in shares)	14,078,349	3,514,180
Stock Options
Anti-dilutive
Total potentially dilutive securities (in shares)	364,022	4,187
Unvested RSUs
Anti-dilutive
Total potentially dilutive securities (in shares)	100	200
Unvested RSAs
Anti-dilutive
Total potentially dilutive securities (in shares)	6,302	6,886